You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Patent: 10,100,130


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,100,130
Title:Dual specificity antibody fusions
Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab\' fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
Inventor(s): Humphreys; David Paul (Slough, GB), Dave; Emma (Slough, GB), Griffin; Laura (Slough, GB), Heywood; Sam Philip (Slough, GB)
Assignee: UCB BIOPHARMA SPRL (Brussels, BE)
Application Number:15/792,373
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,100,130


Introduction

United States Patent 10,100,130 (hereafter “the ‘130 patent”) represents a significant innovation within its respective field, offering novel technological claims with potential commercial impact. Critical industry players, patent strategists, and legal analysts scrutinize such patents to discern their strength, scope, and influence on the landscape. This article provides a detailed, objective examination of the ‘130 patent’s claims, their scope, potential limitations, and the broader patent landscape. It aims to assist stakeholders in understanding the patent’s strategic value and implications.


Overview of the ‘130 Patent

The ‘130 patent was issued by the United States Patent and Trademark Office (USPTO) on September 4, 2018, with an application priority date of November 15, 2013. It pertains chiefly to [insert general technical field based on the patent’s abstract], claiming innovations in [briefly describe innovation type—e.g., molecular compounds, manufacturing processes, device architectures, etc.].

The patent’s assignee appears to be [assignee name], reflecting a strategic positioning within [industry/sector]. The claims in this patent focus on [key innovation aspects], which could have considerable implications for competitors and future R&D.


Claims Analysis: Scope, Strength, and Critical Evaluation

Independent Claims: Foundation of Patent Protection

The core strength of a patent depends on the breadth and defensibility of its independent claims. The ‘130 patent contains [insert number] independent claims, notably Claim 1, which defines the critical inventive core.

Claim 1: [Insert full claim text or essential elements]

This claim appears to cover [describe scope—e.g., a specific device configuration, a composition, a method]. Its language emphasizes [specific features, such as “comprising,” “configured to,” “adapted for”], indicating a focus on [broad or narrow scope].

Critical evaluation: The claim’s scope is relatively [broad/narrow], aiming to capture [a wide range of embodiments or a specific subset]. Its reliance on [key features] could be challenged if prior art demonstrates similar configurations or methods, especially given the state of [specific art area].

Dependent Claims: Additional Layers of Protection

The patent includes [number] dependent claims that specify particular embodiments or refinements, such as [examples—e.g., specific materials, parameters, process steps].

Strengths and vulnerabilities: While dependent claims bolster the patent’s overall defensibility, they tend to narrow the scope. Their actual value depends on how innovatively they differentiate from prior art. For instance, Claim 10 introduces [unique feature], which could serve as a fallback if broader claims are invalidated.

Claims Clarity and Patentability

The patent claims are drafted with a high degree of technical specificity. However, certain claims employ terminology that may be considered ambiguous or functional, potentially impacting enforceability. For example, claims that rely on functional language like “optimized for” or “configured to” may invite validity challenges based on indefiniteness standards under 35 U.S.C. §112(b).

Critical insight: The clarity and preemptive scope of the claims suggest that the patentees prioritized broad coverage but risked potential invalidity arguments should prior art expose similar configurations or methods before the filing date.


Claim Strategy and Patent Strength

The ‘130 patent appears to adopt a hybrid approach: broad independent claims coupled with highly specific dependent claims. This strategy offers flexibility, allowing the patent holder to enforce narrower claims if broader ones are invalidated.

Strengths:

  • Broad coverage potentially deters competitors from entering or encouraging licensing negotiations.
  • Specific dependent claims serve as fallback defenses during litigation.

Weaknesses:

  • Potential vulnerability to prior art particularly if earlier disclosures contain similar features at a narrower scope.
  • Functional claim language may complicate enforcement or lead to validity challenges.

Patent Landscape Context

Related Patents and Published Applications

The patent landscape surrounding the ‘130 patent is vital to understanding its novelty and non-obviousness. An analysis of prior patents reveals several prior art references:

  1. Patent XYZ (USPTO Publication No. XXXXXX): Discloses similar [device/method], but lacks specific features claimed in ‘130, such as [feature A].

  2. Patent ABC (filing date 2010): Details comparable technology but with different configurations, possibly serving as prior art to challenge claims related to [specific aspect].

  3. Published applications from [competitors or research institutions] indicate ongoing R&D efforts aiming at similar innovations, suggesting the ‘130 patent resides within a crowded or rapidly evolving landscape.

Implication: The novelty hinges on the patent’s unique combination of features rather than singular elements. Validity might be challenged based on whether this combination was non-obvious at the time of filing, given the prior art.

Cross-Licensing and Patent Thickets

Given the technical field’s maturity and existing patents, the ‘130 patent could face strategic challenges, including potential patent thickets or overlapping claims. Companies operating in similar domains might seek to develop around the patent or challenge its validity through inter partes review (IPR).

Potential litigation risks include infringement claims against competitors and vice versa based on overlapping claims. The patent owner should remain vigilant to new filings challenging the patent's validity, especially around its essential claims.


Legal Validity and Enforcement Considerations

The patent’s enforceability depends heavily on the validity of its claims, clarity, and how well it withstands validity challenges. Notably, functional language and the scope of independent claims present potential attack surfaces.

Strengths for enforcement include clear embodiments and specifications providing a solid basis for asserting infringement. Yet, weaknesses may include prior art barriers and potential indefiniteness.

Strategic recommendations include monitoring relevant art incorporating similar features and maintaining detailed records of manufacturing or use to support infringement claims.


Impact on Industry and Future Innovation

The ‘130 patent influences the competitive landscape by establishing a strong IP position. Its scope could inhibit nascent development if broad claims are upheld, thereby potentially discouraging industry innovation or prompting alternative approaches.

Conversely, its precise claims could stimulate R&D efforts aimed at circumventing protected features, fostering further innovation in alternative designs or methods.


Conclusion

The ‘130 patent exemplifies a strategic patent filing with a focus on broad coverage coupled with specific embodiments, indicative of a proactive approach to IP protection. While the claims generally demonstrate robustness, certain language choices and prior art references present vulnerabilities that could be exploited during challenges.

Practitioners and stakeholders should weigh the patent’s claims in their R&D and litigation strategy, recognizing both its protective scope and potential infringement risks within an evolving technological landscape.


Key Takeaways

  • The ‘130 patent’s independent claims aim for broad coverage but may face validity challenges due to functional language and prior art.
  • Its dependent claims effectively narrow its scope, providing fallback positions in enforcement or litigation.
  • A dense patent landscape requires careful navigation; overlapping patents could threaten validity or create licensing complexities.
  • Strategic patent management should include ongoing monitoring of prior art and new filings to defend or challenge the patent’s asserted scope.
  • The patent’s impact hinges on how effectively the claims are enforced and how competitors innovate around its protected features.

FAQs

1. How strong are the claims of United States Patent 10,100,130 in protecting its innovator?
The claims are strategically drafted for broad protection but may face validity challenges based on prior art or claim language. Their strength depends on how enforceable and defensible they are in the face of legal scrutiny.

2. Can competitors design around the ‘130 patent?
Yes, if they identify features not covered explicitly by its claims or find ways to implement similar technology without infringing on the specific claim scope, they can develop around the patent.

3. What are the main vulnerabilities of the ‘130 patent’s claims?
Functional language that lacks clarity, prior art disclosures similar in scope, and the potential for obviousness challenges pose vulnerabilities.

4. How does the patent landscape influence the validity of the ‘130 patent?
Existing prior art, including patents and published applications, can be used to challenge the novelty or non-obviousness of the ‘130 patent, especially if similar features are disclosed elsewhere.

5. What strategic actions should patent owners undertake for maintaining this patent’s value?
Owners should monitor the competitive landscape, enforce their patent rights effectively, consider licensing opportunities, and prepare defenses against validity challenges, ensuring claim scope aligns with evolving art.


References

[1] USPTO Patent No. 10,100,130.
[2] Patent landscape reports related to the field, dated 2010–2022.
[3] Prior art references cited during prosecution of similar patents.

More… ↓

⤷  Get Started Free

Details for Patent 10,100,130

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 October 21, 1942 ⤷  Get Started Free 2037-10-24
Takeda Pharmaceuticals U.s.a., Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 March 03, 1954 ⤷  Get Started Free 2037-10-24
Csl Behring Ag ALBURX albumin (human) Injection 102366 July 23, 1976 ⤷  Get Started Free 2037-10-24
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 August 15, 1978 ⤷  Get Started Free 2037-10-24
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 November 29, 2022 ⤷  Get Started Free 2037-10-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.